Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced the launch of a novel ...
Quest Diagnostics has rolled out an ultrasensitive blood test to monitor multiple myeloma treatment, potentially sparing patients from more invasive and costly bone marrow aspirations. | Quest ...
Medical Device Network on MSN
Quest launches flow cytometry MRD test for myeloma
Quest expects the new blood test will support response monitoring in clinical trials.
Quest Diagnostics debuts a new blood test for myeloma MRD, offering NGS-level sensitivity and a less invasive alternative to ...
Randomized Phase III Study of Continuation Maintenance Bevacizumab With or Without Pemetrexed in Advanced Nonsquamous Non–Small-Cell Lung Cancer: COMPASS (WJOG5610L) In the PETHEMA/GEM2012MENOS65 ...
Minimal residual disease (MRD) has emerged as a significant marker in the treatment of multiple myeloma (MM), allowing clinicians to make more informed decisions about therapy. MRD testing helps gauge ...
In part 2 of our interview with Surbhi Sidana, MD, MBBS, American Society of Hematology and Stanford University, she delves into one of the hottest topics in the hematologic malignancy space today: ...
After five decades of use, flow cytometry is entrenched in biomedical science. Besides enabling the quick processing of cells in suspension, flow cytometry provides quantitative results across ...
Around the same time, Mack Fulwyler, an engineer working at Los Alamos National Laboratory, needed to separate particles, so he drew on existing techniques to create droplets to separate cells from a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results